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over different combinations of patient weight and surface area.
RESULTS: Savings of €3,404 per course per patient were shown;
potentially saving the Italian health care system €7.67 million per
year. This assumes that of the 2,252 third-line patients, 57%
receive panitumumab and 43% receive Active Supportive Care in
Year 1 based on the prevalence of the wild-type K-RAS mutation,
compared with 100% receiving cetuximab. CONCLUSIONS:
Results indicate that substantial savings are associated with pani-
tumumab therapy over cetuximab therapy at national and per-
patient levels.
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OBJECTIVES: This study evaluates the cost-effectiveness and
the budget impact of ixabepilone, a new microtubule stabilizer
for treatment of breast cancer, as part of the Formulary Man-
agement System at a major tertiary cancer center in the United
States. METHODS: A decision analytical model was developed
to estimate the incremental cost-effectiveness of ixabepilone for
breast cancer, in patients who failed treatment with anthracy-
cline and taxane. The model compared two strategies: combi-
nation therapy of ixabepilone with capecitabine compared to
capecitabine alone. The outcome of interest was progression
free life year (PFLY), based on published literature and clinical
use estimates. Direct institutional medical costs for a one-year
time period were utilized. One-way and two-way sensitivity
analyses on the probabilities of disease progression were con-
ducted. In addition, a budget impact analysis was also con-
ducted for adding ixabepilone in the Formulary. RESULTS:
Based on outcome estimates from literature and the application
of the institutional costs, the cost per PFLY saved for ixabepi-
lone for treatment of advanced breast cancer was $318,404.
One-way sensitivity analysis on the efﬁcacy probability (0–1.0)
of the combination therapy indicated that ixabepilone’s cost-
effectiveness ratios ranged from $205,000 to $1,190,000 per
PFLY saved. Two-way sensitivity analysis with a willingness-to-
pay threshold of $250,000 indicated that the majority of the
time monotherapy is the more cost-effective option. Only if
the probability of response to the combination is >30% and the
probability of response to the monotherapy is <33%, does the
combination therapy become more cost-effective. The budget
impact model showed that the institution will utilize about
$7.39 million worth of ixabepilone annually based on acquisi-
tion costs. CONCLUSIONS: Ixabepilone appears to be less
cost-effective than other neoplastic agents for treatment of
breast cancer. Future economic analyses will be conducted to
determine how closely the current economic model predicts
actual utilization and cost-effectiveness at the institution.
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OBJECTIVES: The purpose of this study was to analyse the
disease-related costs as well as the side effect hand-foot syndrome
(HFS) in oncologic patients receiving capecitabine. HFS is a dose
and therapy limiting toxicity which is classiﬁed into severity
grades 1 to 3. METHODS: Between April 2006 and August 2007
an observational study was conducted in Bonn, Germany on two
oncologic outpatient wards and three oncologic practices. Breast
and colorectal cancer patients starting oral chemotherapy with
capecitabine were included and followed for six months. They
rated their HFS at the end of each capecitabine cycle. The HFS
grades were transformed into utility weights obtained from an
earlier study in our group. From the perspective of the German
statutory health insurance the direct disease-related costs (out-
patient costs for pharmacotherapy, oncologist visits, diagnostics
and inpatient costs) were assessed in a microcosting approach
and referred to 2008. RESULTS: Thirty patients (16 breast, 14
colorectal cancer) were included. Their mean HFS severity grade
was 1.1 (SD 0.7, median 1.0, range 0 to 2.75) corresponding to
a mean utility weight of 0.88 (SD 0.14, median 0.92, range 1.00
to 0.44). Seven patients showed a HFS grade 3 (utility weight:
0.34) at least in one capecitabine cycle. On average €18,305
(80.4% outpatient, 19.6% inpatient) were calculated per breast
cancer patient and €25,863 (71.2% outpatient, 28.8% inpatient)
per colorectal cancer patient. Concerning the outpatient treat-
ment, costs for pharmacotherapy represented the highest matter
of expense (96.0% breast, 95.0% colorectal cancer). CONCLU-
SIONS: In most patients HFS occurred in moderate severity.
Nevertheless, 7 patients experienced HFS grade 3 affecting
quality of life. Strategies to prevent this toxicity need to be
developed. Especially costs for pharmacotherapy represent a
cost-driving factor in this patient group indicating a need for
strategies to optimize cost structure while containing or improv-
ing quality of treatment.
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OBJECTIVES: Panitumumab is the ﬁrst fully human anti-EGFR
monoclonal antibody to be approved as monotherapy for
patients with wild type (wt) KRAS mCRC after failure of
ﬂuoropyrimidine-, oxaliplatin-, and irinotecan-containing che-
motherapy regimens. This novel treatment approach is the begin-
ning of a new era of personalised treatment whereby KRAS
status is evaluated and only patients who are likely to respond
(wt KRAS) receive treatment. The objective of this study was to
evaluate the overall budget impact (BI) of the use of panitu-
mumab versus testing KRAS and treating patients with wt KRAS
in Greece. METHODS: To consider overall costs associated with
panitumumab treatment versus testing KRAS status and treating
only wt KRAS patients with panitumumab, a decision analytic
model was developed to evaluate BI. Primary drug costs, con-
comitant medications, infusion costs, radiation therapy, clinic
visits, and hospitalisations were included in treatment costs. An
expert panel was employed to map mCRC patient ﬂow as a local
cancer registry was not available. In this analysis, cost calcula-
tions for the public and private sectors were conducted sepa-
rately. RESULTS: Out of 470 potentially eligible patients for
panitumumab monotherapy, the decision analytic model targets
268 (57%) patients with wt KRAS, according to indication.
Potential total cost of receiving panitumumab without taking
KRAS status into consideration was €8.4 million in the public
sector, while total cost including KRAS testing to all patients but
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